The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
T-cell engagers
Significant advances in antibody engineering have led to the development of a novel therapeutic class with a unique mechanism of action: to target both malignant cells and T cells and bring them closer together, activating the cytotoxic capacity of the immune cell. T-cell engagers include IgG-like bispecific antibodies and optimized designs without the Fc domain (BiTEs, DARTs, and TriKEs).
Filter by content: